Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

What is claimed is:

1. (CURRENTLY AMENDED) A non-invasive method for facilitating the diagnosis of a subject for a tissue remodeling-associated condition, comprising:

obtaining a urine sample from a subject;

contacting the urine sample with an antibody specifically reactive with

NGAL to detecting detect an MMP-9/NGAL complex in the urine sample;

and

correlating the presence or absence of the MMP-9/NGAL complex with the presence or absence of a tissue remodeling-associated condition, thereby facilitating the diagnosis of the subject for a tissue remodeling-associated condition.

2. **(PREVIOUSLY PRESENTED)** The method of claim 1, wherein the tissue remodeling-associated condition is cancer.

3. - 5. (CANCELED)

- 6. **(PREVIOUSLY PRESENTED)** The method of claim 2, wherein the cancer is in cells of epithelial origin.
- 7. **(CURRENTLY AMENDED)** The method of claim 6, wherein the cancer is selected from the group consisting of cancers of the nervous system, breast, prostate, retina, lung, skin, kidney, liver, pancreas, genito-urinary tract, and gastrointestinal tract.

Appln. No. 09/977,878 Amendment dated March 3, 2005 Response to Office Action dated November 03, 2004

- 8. (CANCELED)
- 9. (PREVIOUSLY PRESENTED) The method of claim 2, wherein the cancer appears in cells of endodermal origin.
- 10. (PREVIOUSLY PRESENTED) The method of claim 2, wherein the cancer affects cells of bone or of hematopoietic origin.
 - 11. 40. **(CANCELED)**
- 41. (PREVIOUSLY PRESENTED) The method of claim 1, further comprising removal of contaminants from the urine prior to the detection step.
- 42. (PREVIOUSLY PRESENTED) The method of claim 41, wherein the urine is dialyzed.
- 43. **(CANCEL)** The method of claim 1, wherein the enzyme is detected by an electrophoretic pattern.
- 44. **(CANCEL)** The method of claim 43, wherein the electrophoretic pattern is a zymogram comprising a substrate.
- 45. **(CANCEL)** The method of claim 44, wherein the zymogram substrate is selected from the group consisting of gelatin, casein, fibronectin, vitronectin, plasmin, plasminogen, type IV collagen, and a derivative of type IV collagen.
- 46. **(CANCEL)** The method of claim 1, wherein the enzyme is detected immunochemically.
- 47. (CURRENTLY AMENDED) The method of claim 46 1, wherein the enzyme MMP-9/NGAL complex is detected by a radio-immunoassay.
 - 48. (CURRENTLY AMENDED) The method of claim 46-1, wherein the enzyme

Appln. No. 09/977,878 Amendment dated March 3, 2005 Response to Office Action dated November 03, 2004

MMP-9/NGAL complex is detected by an enzyme-linked immunoabsorbant assay.

49. – 80. (CANCELED)

81. (NEW) The method of claim 1, further comprising contacting the urine sample with an antibody specifically reactive with MMP-9.